SYRE Q4 2020 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$23M

EPS (Diluted)

$-9.82

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$162M

Total Liabilities

$22M

Stockholders' Equity

$140M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$22M	-4.0%
Net Income	-$23M	-$21M	-5.7%